StemCell Therapy

The researchers measured the visceral adipose tissue (VAT) and liver fat (LF) from magnetic resonance images of 12,276 participants from the UK Biobank, the researchers assessed and divided individuals into four groups defined by sex-specific median values of VAT and LF: low VAT-low LF, low VAT-high LF, high VAT-low LF, and high VAT-high LF. Participants were followed for 1.3 years (on average) to detect VAT-LF groups' associations with CHD incidence.

In total, 176 CHD events were recorded, revealing that high visceral adiposity increased risk for CHD; this effect was exacerbated in those who also had low liver fat elevating the risk for CHD greater than two-fold compared with low VAT-low LF. High liver fat in combination with low visceral adiposity (low VAT-high LF), did not increase the risk for CHD. After adjusting for age and body mass index, high VAT-high LF association with CHD diminished, but the increased risk of CHD among those with high VAT-low LF persisted.

"We believe knowledge of patient risk for disease is limited when assessment is restricted to single, isolated fat depots. When developing NAFLD treatments, a decrease in liver fat alone may not be sufficient to lower patients' cardiometabolic risk. In fact, the research shows that decreasing liver fat without resolving visceral obesity may put the patient at greater risk of heart disease. This is what we want to investigate further,"stated Jennifer Linge, Lead Scientist, Personalized Medicine at AMRA Medical.

The results suggest that heterogeneity of body fat distribution affects CHD risk. Specifically, risk for CHD increased among those with high visceral adiposity, which intensifies in the presence of low liver fat indicating that liver triglyceride regulation plays a vital role in cardiovascular health in the context of visceral obesity.

Learn more about these findings by viewing the recorded presentation. The corresponding abstract "Can Low Liver Fat Be Bad for Your Heart? The High Visceral Fat, Low Liver Fat Phenotype: A Risk Factor for Coronary Heart Disease" (number 89) can be found in the journal HEPATOLOGY.

About UK Biobank

UK Biobankis large-scalebiomedical database and research resource, containing in-depth genetic andhealth information from halfa million UK participants. The database, which isregularly augmented with additional data, is globally accessible to approvedresearchersand scientists undertaking vital research into the most common andlife-threatening diseases. UK Biobank's researchresource is a majorcontributor to the advancement of modern medicine and treatment and has enabledseveral scientific discoveriesthat improve human health.

About AMRA Medical

AMRAis a ground-breaking international digital health company at the forefront of medicalimaging and precision medicine. The company has developed a new global standard in bodycomposition assessment, the ability to automatically produce multiple fat and musclebiomarkers with unrivaled precision and accuracy, as well as contextual disease insights allfrom a single, rapid, whole-body MRI.

SOURCE AMRA Medical

Start

See more here:
AMRA Medical Research Reveals New MRI-based Data Connected to Risk for Coronary Heart Disease at The Liver Meeting Digital Experience - PRNewswire

This entry was posted on November 24, 2020 at 9:55 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |